Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from abacavir + lamivudine + nevirapine to dolutegravir + abacavir + lamivudine in virologically suppressed adults with HIV-1
2013-003197-27Phase 2Active
- Sponsor
- CHU de Nantes
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dolutegravir, abacavir, lamivudine and nevirapine in Human immunodeficiency virus infection type 1, sponsored by CHU de Nantes. Primary endpoint: Maintenance of virologic suppression at week 12. Started Sep 2015; status: active.
02
Drugs
dolutegravirabacavirlamivudinenevirapine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2013-003197-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003197-27.